SHMT1 and acute myeloid leukemia: Although acute leukemias are typically highly proliferative, the effect of one-carbon folate pathway inhibition using a novel inhibitor of SHMT1 and SHMT2, RZ-2994, was greater in T-ALL compared to AML.